Search
for

    Did you mean Prolactin Receptor?
    GlossaryProlactin Receptor

    protein on cell surfaces that binds to prolactin hormone

    The Prolactin Receptor (PRLR) is a protein found on the surface of certain cells that binds to the hormone prolactin. This interaction is crucial for various biological processes, including lactation, reproductive functions, and immune system regulation. In the context of hair biology, prolactin and its receptor can influence hair growth and hair cycle regulation.

    Related Terms

    Learn

    5 / 801 results

    Research

    5 / 1000+ results

    Community Join

    5 / 346 results

      community What do we actually know about HMI-115?

      in Chat  16 upvotes 2 years ago
      The post and conversation are about HMI-115, a potential treatment for hair loss. The conclusion is that HMI-115 is not a 5ar-inhibitor and is instead a prolactin receptor inhibitor. Some users are skeptical about its effectiveness and believe that baldness will still be a problem in the future.

      community Since there is so much hype for cosmeRNA and HMI-115...

      in Chat  47 upvotes 3 years ago
      Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.

      community Put P5P in my shampoo, reduced itch a lot!

      in Chat  3 upvotes 3 years ago
      The user added P5P (vitamin B6) to their shampoo to reduce scalp itch, which improved significantly. They have been using finasteride for hair loss but are exploring additional treatments like topical antiandrogens and prolactin inhibitors.

      community HLT Megathread on HMI-115 (key takeaways in comments)

      in Research/Science  39 upvotes 3 years ago
      HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.